AEs during initial treatment and retreatment with durvalumab
| AEs | Initial treatment (n=70) | Retreatment (n=70) |
| ≥1 treatment-emergent AE, n (%) | 69 (98.6) | 64 (91.4) |
| ≥1 grade 3 or 4 treatment-emergent AE, n (%) | 24 (34.3) | 31 (44.3) |
| ≥1 TRAE, n (%) | 53 (75.7) | 28 (40.0) |
| ≥1 grade 3 or 4 TRAE, n (%) | 2 (2.9) | 4 (5.7) |
| ≥1 TRAE leading to durvalumab discontinuation | 0 | 2 (2.9) |
| ≥1 serious TRAE, n (%) | 2 (2.9) | 2 (2.9) |
| Deaths | 0 | 0 |
TRAE, treatment-related adverse event.